Nelarabine
 | ||
 | ||
| Clinical data | ||
|---|---|---|
| Trade names | Arranon, Atriance | |
| Other names | 506U78 | |
| AHFS/Drugs.com | Monograph | |
| MedlinePlus | a607077 | |
| License data |
| |
| Routes of administration | Intravenous | |
| ATC code | ||
| Legal status | ||
| Legal status | ||
JSmol) | ||
| ||
| ||
  (what is this?) (verify) | ||
Nelarabine, sold under the brand names Arranon (US) and Atriance (EU), is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).[2][3]
Nelarabine is a
generic medication.[6]
References
- FDA. Retrieved 22 Oct 2023.
- ^ a b "Arranon- nelarabine injection". DailyMed. 11 June 2020. Retrieved 4 December 2020.
- ^ a b c "Atriance EPAR". European Medicines Agency (EMA). Retrieved 4 December 2020.
- ^ "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.
- S2CID 23463537.
- ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
External links
- "Nelarabine". Drug Information Portal. U.S. National Library of Medicine.
- "Nelarabine". NCI Dictionary of Cancer Terms. National Cancer Institute.
- "Nelarabine". National Cancer Institute.[permanent dead link]
